Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARO-APOC3 in Adults with Familial Chylomicronemia Syndrome
2024-514336-24-00Phase 3Completed
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Sep 2024
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 20
01
Overview
Phase 3 trial of plozasiran in primary chylomicronemia (FCS), sponsored by Arrowhead Pharmaceuticals. Primary endpoint: Percent change from baseline at Month 10 in fasting triglycerides. Started Sep 2024; status: completed.
02
Drugs
plozasiran
03
Conditions
primary chylomicronemia (FCS)
Beyond the preview
Go deeper on 2024-514336-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514336-24-00.